![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » RegeneRx’s Dry Eye Treatment Flops in Phase 2/3
RegeneRx’s Dry Eye Treatment Flops in Phase 2/3
May 12, 2016
RegeneRx Biopharmaceuticals’ dry eye candidate RGN-259 missed its primary endpoints in a Phase 2/3 trial, failing to show statistically significant improvements in either total ocular discomfort or total corneal fluorescein staining.
Despite the failed results in the 317-patient trial to treat severe dry eye, the company said that the drug showed significant results in several endpoints, such as “fast-acting treatment effect” on dry eye symptoms when exposed to an adverse environment or natural environment after 28 days of dosing, the company says. No adverse events were observed.
Upcoming Events
-
21Oct